Early data shows that combining PARP inhibitors with radioligand therapy like lutetium-PSMA is surprisingly safe, unlike toxic combinations with chemotherapy. This promising strategy may potentiate the DNA-damaging effect of the beta-emitting radiopharmaceutical, potentially extending its benefit to a broader patient population beyond those with HR-deficient tumors.

Unlike traditional chemotherapy, radioligand therapy's toxicity may be inversely correlated with tumor volume. In low-burden disease, fewer cancer cells act as a 'sink' for the drug, potentially leading to higher radiation exposure and side effects in healthy, PSMA-expressing tissues like salivary glands.

The PSMA Addition study, adding lutetium in metastatic hormone-sensitive prostate cancer, showed an RPFS benefit. However, initial data suggested adverse quality of life scores. Upcoming results on pain and skeletal events are critical to determine if the toxicity profile undermines its clinical utility in this earlier disease setting.

Even if radioligand therapies like Lutetium-PSMA are approved for first-line metastatic prostate cancer, their real-world adoption will be significantly hampered by logistics. Most U.S. patients are treated in community practices that lack the infrastructure for these therapies, creating a major access and bandwidth problem that will temper uptake.

PSMA-PET imaging at baseline can identify who benefits from adding lutetium-PSMA. In the ENZA-P trial, patients with high-volume disease saw a significant survival benefit from the combination. Conversely, those with low-volume disease derived no benefit, suggesting imaging can be used for patient selection.

The mHSPC phase is considered the patient's "best bit of the rest of your life." When considering triplet therapies, clinicians favor options with a fixed, shorter duration of toxicity (like lutetium) over continuous treatments (like capivasertib) to minimize the negative impact on this crucial period of high quality of life.

If lutetium-PSMA is approved and used upfront in hormone-sensitive disease, clinicians may become more comfortable with radioligands generally. This could lead them to use the enzalutamide-radium combination more frequently later on, paradoxically increasing radium's use by flipping the current treatment sequence.

Clinicians are viewing PSMA PET scans as a quantitative tool, not just a binary test. Patients with very "bright" scans (high SUV, e.g., >10) may be the ideal candidates for Lutetium-PSMA radioligand therapy, suggesting avidity predicts the magnitude of benefit.

Instead of administering all six planned doses of PSMA Lutetium upfront in the hormone-sensitive setting, a novel "sandwich" strategy is being considered. This involves giving a few doses, re-imaging, and reserving subsequent doses for later, potentially optimizing efficacy and managing long-term toxicity.